These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 22291397)

  • 21. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.
    Araujo JA; Studzinski CM; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):411-22. PubMed ID: 15795050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioural effects of scopolamine and the TRH analogue RX77368 on radial arm maze performance in the rat.
    Watson CD; Hewitt MJ; Fone KC; Dickinson SL; Bennett GW
    J Psychopharmacol; 1994 Jan; 8(2):88-93. PubMed ID: 22298534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans.
    Martinez R; Molchan SE; Lawlor BA; Thompson K; Martinson H; Latham G; Weingartner H; Sunderland T
    Biol Psychiatry; 1997 Jan; 41(1):50-7. PubMed ID: 8988795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen replacement attenuates effects of scopolamine and lorazepam on memory acquisition and retention.
    Gibbs RB; Burke AM; Johnson DA
    Horm Behav; 1998 Oct; 34(2):112-25. PubMed ID: 9799622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sub-biochemical hypothyroidism: an exaggerated thyroid stimulating hormone response to thyrotrophin releasing hormone.
    Sheth JJ; Thakore PB; Trivedi BB; Shah NN; Vaidya RA
    J Assoc Physicians India; 1999 Mar; 47(3):275-9. PubMed ID: 10999119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic and cholinergic involvement in the inhibitory effect of dexamethasone on the TSH response to TRH.
    Coiro V; Volpi R; Cataldo S; Capretti L; Caffarri G; Pilla S; Chiodera P
    J Investig Med; 2000 Mar; 48(2):133-6. PubMed ID: 10736973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trials in dementia: learning effects with repeated testing.
    Claus JJ; Mohr E; Chase TN
    J Psychiatry Neurosci; 1991 Mar; 16(1):1-4. PubMed ID: 2049365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model.
    Molchan SE; Martinez RA; Hill JL; Weingartner HJ; Thompson K; Vitiello B; Sunderland T
    Brain Res Brain Res Rev; 1992; 17(3):215-26. PubMed ID: 1467811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of scopolamine on retrieval from semantic memory.
    Lines CR; Preston GC; Broks P; Dawson CE
    J Psychopharmacol; 1991 Jan; 5(3):234-7. PubMed ID: 22282561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The scopolamine model of dementia: chronic transdermal administration.
    Brazell C; Preston GC; Ward C; Lines CR; Traub M
    J Psychopharmacol; 1989 Jan; 3(2):76-82. PubMed ID: 22156502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scopolamine challenges in Alzheimer's disease.
    Sunderland T; Tariot P; Murphy DL; Weingartner H; Mueller EA; Cohen RM
    Psychopharmacology (Berl); 1985; 87(2):247-9. PubMed ID: 3931154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers.
    Wesnes K; Anand R; Simpson P; Christmas L
    J Psychopharmacol; 1990 Jan; 4(4):219-32. PubMed ID: 22281851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of neuropeptides on cognitive function.
    Bennett GW; Ballard TM; Watson CD; Fone KC
    Exp Gerontol; 1997; 32(4-5):451-69. PubMed ID: 9315449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.
    Sunderland T; Tariot PN; Cohen RM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):418-26. PubMed ID: 3579494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic modelling of Alzheimer's disease.
    Sunderland T; Tariot PN; Weingartner H; Murphy DL; Newhouse PA; Mueller EA; Cohen RM
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):599-610. PubMed ID: 3541054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a low affinity thyrotropin-releasing hormone (TRH)-like peptide that exhibits potent inhibition of scopolamine-induced memory impairment in mice.
    Meena CL; Ingole S; Rajpoot S; Thakur A; Nandeker PP; Sangamwar AT; Sharma SS; Jain R
    RSC Adv; 2015 Jun; 5():56872-56884. PubMed ID: 26191403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive psychopharmacology.
    McLean A; Cardenas DD; Haselkorn JK; Peters M
    NeuroRehabilitation; 1993; 3(2):1-14. PubMed ID: 24526032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scopolamine-induced "cholinergic stress test" in the elderly.
    Román GC; Jackson RE; Longoria EM; Fisher RE
    Front Pharmacol; 2014; 5():182. PubMed ID: 25165458
    [No Abstract]   [Full Text] [Related]  

  • 39. Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease.
    Mellow AM; Sunderland T; Cohen RM; Lawlor BA; Hill JL; Newhouse PA; Cohen MR; Murphy DL
    Psychopharmacology (Berl); 1989; 98(3):403-7. PubMed ID: 2501817
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.